Page last updated: 2024-09-05

troleandomycin and paroxetine

troleandomycin has been researched along with paroxetine in 6 studies

Compound Research Comparison

Studies
(troleandomycin)
Trials
(troleandomycin)
Recent Studies (post-2010)
(troleandomycin)
Studies
(paroxetine)
Trials
(paroxetine)
Recent Studies (post-2010) (paroxetine)
56926234,2571,0311,031

Protein Interaction Comparison

ProteinTaxonomytroleandomycin (IC50)paroxetine (IC50)
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)3.9
MyeloperoxidaseHomo sapiens (human)0.02
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)0.086
Muscarinic acetylcholine receptor M2Homo sapiens (human)0.532
Muscarinic acetylcholine receptor M4Homo sapiens (human)0.244
Muscarinic acetylcholine receptor M5Homo sapiens (human)0.123
Quinolone resistance protein NorAStaphylococcus aureus7
Cytochrome P450 2D6Homo sapiens (human)0.5003
Muscarinic acetylcholine receptor M1Homo sapiens (human)0.145
Muscarinic acetylcholine receptor M3Homo sapiens (human)0.179
Beta-adrenergic receptor kinase 1Bos taurus (cattle)1.08
Sodium-dependent noradrenaline transporter Homo sapiens (human)0.093
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)0.623
Beta-adrenergic receptor kinase 1Homo sapiens (human)1.24
Substance-P receptorHomo sapiens (human)0.9
Sodium-dependent serotonin transporterHomo sapiens (human)0.0007
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)0.0003
P2X purinoceptor 4Rattus norvegicus (Norway rat)2.45
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)3.9
Sodium-dependent dopamine transporter Homo sapiens (human)0.672
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)3.9
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)3.9
P2X purinoceptor 4Homo sapiens (human)2.8067
Sigma non-opioid intracellular receptor 1Homo sapiens (human)5.366
TransporterRattus norvegicus (Norway rat)0.535

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dansette, PM; Fontana, E; Poli, SM1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Reinen, J; Smit, M; Wenker, M1

Reviews

1 review(s) available for troleandomycin and paroxetine

ArticleYear
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
    Current drug metabolism, 2005, Volume: 6, Issue:5

    Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic

2005

Other Studies

5 other study(ies) available for troleandomycin and paroxetine

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Evaluation of Strategies for the Assessment of Drug-Drug Interactions Involving Cytochrome P450 Enzymes.
    European journal of drug metabolism and pharmacokinetics, 2018, Volume: 43, Issue:6

    Topics: Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Dihydralazine; Dose-Response Relationship, Drug; Drug Interactions; Humans; Microsomes, Liver; Mifepristone; Paroxetine; Theophylline; Troleandomycin; Verapamil

2018